Compare HURN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HURN | PHVS |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2004 | 2020 |
| Metric | HURN | PHVS |
|---|---|---|
| Price | $157.78 | $32.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $204.40 | $41.82 |
| AVG Volume (30 Days) | 183.9K | ★ 1.0M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $1,699,143,000.00 | N/A |
| Revenue This Year | $11.80 | N/A |
| Revenue Next Year | $8.23 | N/A |
| P/E Ratio | $117.66 | ★ N/A |
| Revenue Growth | ★ 11.65 | N/A |
| 52 Week Low | $84.88 | $20.65 |
| 52 Week High | $186.78 | $43.25 |
| Indicator | HURN | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 33.49 |
| Support Level | $143.69 | $25.17 |
| Resistance Level | $165.37 | $36.80 |
| Average True Range (ATR) | 4.98 | 2.22 |
| MACD | -0.28 | -0.66 |
| Stochastic Oscillator | 79.98 | 3.57 |
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.